Current medicinal chemistry · 2026
MDMA-Assisted Treatment for PTSD, Anxiety, and Depression: A Visualized Literature Analysis over 30 Years.
СтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhang Jinlong, Dang Xingxing, Lin Jiang, Chen Qianqian, Wang Binbin, Yan Jie
Аннотация
BACKGROUND: The incidence of psychiatric disorders, such as post-traumatic stress disorder (PTSD), anxiety, and depression, has been steadily increasing, while current treatment approaches remain limited in efficacy. As a result, there is an urgent need to explore more effective therapeutic interventions. In recent years, MDMA (3,4- methylenedioxymethamphetamine)-assisted therapy (MDMA-AT) has emerged as a promising and innovative approach, demonstrating favorable clinical potential in the treatment of these disorders. Although preliminary studies have confirmed its therapeutic efficacy, a comprehensive and systematic analysis of the research trends and current limitations of MDMA-AT remains lacking.
METHODS: This study employed a bibliometric approach to systematically retrieve and analyze research literature published between 1994 and 2023 on the application of MDMA in the treatment of PTSD, anxiety, and depression. Relevant data were obtained from three prominent databases: Web of Science Core Collection, PubMed, and Scopus. VOSviewer and Microsoft Excel were used to perform visual and quantitative analyses, focusing on publication trends, research hotspots, prolific authors, leading institutions, and international collaboration networks.
RESULTS: The findings indicated a substantial increase in MDMA-related research over the past decade. The United States has led the field in publication output, with the Multidisciplinary Association for Psychedelic Studies (MAPS) identified as the most productive institution. Key figures, such as Rick Doblin, have demonstrated high influence and centrality within the global research network. The research focus has gradually shifted from investigations of the neurotoxic properties of MDMA to explorations of its therapeutic mechanisms, safety profiles, and clinical applications.
CONCLUSION: This study provides a comprehensive synthesis of the past thirty years of research on MDMA-AT in the treatment of PTSD, anxiety, and depression, identifying major research trajectories and critical challenges in the field. While current findings highlight the therapeutic promise of MDMA and its translational potential, further research is needed to improve trial design, enhance sample diversity, and evaluate long-term effects in order to support the standardization and evidence-based integration of MDMA- assisted therapy into clinical practice.
METHODS: This study employed a bibliometric approach to systematically retrieve and analyze research literature published between 1994 and 2023 on the application of MDMA in the treatment of PTSD, anxiety, and depression. Relevant data were obtained from three prominent databases: Web of Science Core Collection, PubMed, and Scopus. VOSviewer and Microsoft Excel were used to perform visual and quantitative analyses, focusing on publication trends, research hotspots, prolific authors, leading institutions, and international collaboration networks.
RESULTS: The findings indicated a substantial increase in MDMA-related research over the past decade. The United States has led the field in publication output, with the Multidisciplinary Association for Psychedelic Studies (MAPS) identified as the most productive institution. Key figures, such as Rick Doblin, have demonstrated high influence and centrality within the global research network. The research focus has gradually shifted from investigations of the neurotoxic properties of MDMA to explorations of its therapeutic mechanisms, safety profiles, and clinical applications.
CONCLUSION: This study provides a comprehensive synthesis of the past thirty years of research on MDMA-AT in the treatment of PTSD, anxiety, and depression, identifying major research trajectories and critical challenges in the field. While current findings highlight the therapeutic promise of MDMA and its translational potential, further research is needed to improve trial design, enhance sample diversity, and evaluate long-term effects in order to support the standardization and evidence-based integration of MDMA- assisted therapy into clinical practice.